Back to UBS Group AG UBS Group AG

VRDNVRDN
Showing 8 of 22 quarters

Position history for UBS Group AGUBS Group AG's holdings in VIRIDIAN THERAPEUTICS INC

Yes. Ubs holds 1,428,843 shares of VRDN (Viridian Therapeutics), worth $26.2M, as of its Q2 2026 13F filing. It increased the position from 307,134 shares in Q1 2026. Ubs has held VRDN since Q1 2021, across 22 quarterly 13F filings.

Current Value

$26.2M

Current Shares

1.4M

Total Value Change

+$24.3M

Total Shares Change

+1.3M

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
1.4M
+365.2%
$26.2M0.0%$18.37
46
2026-Q1
Increased
307,134
+86.3%
$6M0.0%$29.32
42
2025-Q4
Decreased
164,820
-63.2%
$5.1M0.0%$31.02
0
2025-Q3
Decreased
447,677
-16.1%
$9.7M0.0%$21.61
0
2025-Q2
Increased
533,643
+5.8%
$7.5M0.0%$14.33
29
2025-Q1
Decreased
504,185
-1.5%
$6.8M0.0%$14.44
0
2024-Q4
Increased
512,071
+504.3%
$9.8M0.0%$19.54
45
2024-Q3
Decreased
84,733
-63.2%
$1.9M0.0%$23.33
0

Other major holders of VRDN: FMR LLC

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used